Title

Bolstering your armamentarium with SGLT2 inhibitors.

Document Type

Article

Publication Date

6-2-2017

Publication Title

The Nurse practitioner

Abstract

Sodium-glucose cotransporter-2 inhibitors have a unique mechanism of action in the kidneys that causes glucosuria, which lowers plasma glucose. They are also associated with reduced body weight, BP, and a low incidence of hypoglycemia. The pharmacologic profiles/clinical implications of canagliflozin, dapagliflozin, and empagliflozin are discussed in this article.

PubMed ID

28582323

ePublication

ePub ahead of print

Share

COinS